Sort by
Medicine and Dentistry
Adjuvant Therapy
32%
Biliary Tract Cancer
32%
Breast Cancer
70%
Cancer Cell
32%
Cancer Treatment
32%
Cholangiocarcinoma
32%
Cisplatin
32%
Clear Cell Renal Cell Carcinoma
32%
Clinical Trial
53%
Cohort Analysis
32%
Dietetics
29%
Diffuse Large B-Cell Lymphoma
32%
Diseases
100%
Embryonal Rhabdomyosarcoma
64%
Endometrium
32%
Fibroblast Growth Factor Receptor
32%
Fumaric Acid
32%
Ganglioglioma
34%
Gastrointestinal Stromal Tumor
32%
Germ Cell
27%
Germinoma
64%
Glioblastoma
64%
Gut Microbiome
32%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
32%
Ifosfamide
32%
Immunotherapy
28%
Intracranial Tumor
37%
Liver Graft
32%
Malignant Neoplasm
82%
Men's Health
40%
Metastatic Carcinoma
55%
Monoclonal Antibody
26%
Neoadjuvant Therapy
32%
Overall Survival
81%
Paclitaxel
32%
Pertuzumab
32%
Pleura Mesothelioma
32%
Programmed Death-Ligand 1
32%
Progression Free Survival
31%
Quality of Life
45%
Recurrent Disease
37%
Rhabdomyosarcoma
64%
Supportive Care
56%
Survival Rate
28%
Survivorship in Cancer Care
32%
Testis Cancer
40%
Trastuzumab
32%
Tumor
47%
Urinary Tract Cancer
32%
Urogenital Tract Cancer
40%
Pharmacology, Toxicology and Pharmaceutical Science
Antiangiogenic Therapy
8%
Bevacizumab
32%
Biliary Tract Cancer
32%
Biological Marker
46%
Breast Cancer
38%
Carcinogenesis
10%
Chemotherapy
46%
Cisplatin
32%
Clinical Research
8%
Clinical Trial
39%
Combination Therapy
11%
Connective Tissue Cancer
8%
Disease Exacerbation
10%
Disease Free Survival
12%
Diseases
67%
Endocrine Therapy
10%
Epidermal Growth Factor Receptor 2
12%
Estrogen Receptor
10%
Estrogen Receptor Positive Breast Cancer
10%
Gamma Urogastrone
12%
Gastrointestinal Stromal Tumor
32%
Germ Cell Tumor
64%
Glioblastoma
64%
Glycoprotein
6%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
42%
Ifosfamide
32%
Immunotherapy
24%
Lomustine
8%
Malignant Neoplasm
42%
Monoclonal Antibody
20%
Monotherapy
38%
Neoplasm
8%
Overall Survival
79%
Paclitaxel
32%
Pertuzumab
32%
Phase III Trials
8%
Phosphatidylinositol 3 Kinase
32%
Phosphatidylinositol 3 Kinase Inhibitor
32%
Progression Free Survival
26%
Protein Tyrosine Kinase Inhibitor
20%
Recurrent Disease
14%
Solid Malignant Neoplasm
18%
Sunitinib
12%
Survival Rate
34%
Taxane
32%
Temozolomide
16%
Testis Cancer
32%
Therapy Resistance
10%
Tolerability
6%
Trastuzumab
32%